Non-Use of Name. COMPANY, AFFILIATES and SUBLICENSEES shall not use the name of “Xxxxxxxxx Institute for Biomedical Research” or any variation, adaptation, or abbreviation thereof, or any of its trustees, officers, faculty, students, employees (including [***], except as permitted under their separate consulting agreements between [***] and COMPANY effective on [***] and [***], and between [***] and COMPANY effective on [***] and [***]), or agents, or any trademark owned by XXXXXXXXX or any terms of this Agreement in any promotional material or other public announcement or disclosure without the prior written consent of XXXXXXXXX. XXXXXXXXX shall not use the name of “Rubius Therapeutics, Inc.”, “VL26, Inc.”, or any variation, adaptation, or abbreviation of either of the foregoing, or any of its directors, officers, employees or agents, or any trademark owned by COMPANY or any terms of this Agreement in any promotional material or other public announcement or disclosure without the prior written consent of COMPANY. The foregoing notwithstanding, without the consent of XXXXXXXXX, COMPANY may make (a) disclosures required by law, (b) factual statements during the TERM that COMPANY has a license from XXXXXXXXX under one or more of the patents and/or patent applications comprising the PATENT RIGHTS, (c) disclosures of the terms of the Agreement to its or its AFFILIATE’S or affiliated entity’s directors, officers, employees, consultants, advisors and agents, or actual or potential licensors, licensees, sublicensees, acquirers, investors and financing sources; provided that, COMPANY shall bind them to reasonable confidentiality obligations. In addition, COMPANY shall have the right to issue a press release upon execution of this Agreement and the achievement of any milestone, which will be reviewed and approved in advance by XXXXXXXXX if XXXXXXXXX is named in such press release and such naming is not required by law.
Appears in 3 contracts
Samples: Exclusive Patent License Agreement (Rubius Therapeutics, Inc.), Exclusive Patent License Agreement (Rubius Therapeutics, Inc.), Exclusive Patent License Agreement (Rubius Therapeutics, Inc.)
Non-Use of Name. COMPANY, AFFILIATES AFFILIATES, and SUBLICENSEES shall not use the name of “Xxxxxxxxx Institute for Biomedical Research” ”, “Tufts University”, or any variation, adaptation, or abbreviation thereof, or any of its trustees, officers, faculty, students, employees (including [***], except as permitted under their separate consulting agreements between [***] and COMPANY effective on [***] and [***], and between [***] and COMPANY effective on [***] and [***]), or agents, or any trademark owned by XXXXXXXXX WHITEHEAD, TUFTS, or any terms of this Agreement in any promotional material or other public announcement or disclosure without the prior written consent of XXXXXXXXXXXXXXXXXX or TUFTS, as applicable. XXXXXXXXX and TUFTS shall not use the name of “Rubius Therapeutics, Inc.”, “VL26, Inc.”, or any variation, adaptation, or abbreviation of either of the foregoing, or any of its directors, officers, employees or agents, or any trademark owned by COMPANY or any terms of this Agreement in any promotional material or other public announcement or disclosure without the prior written consent of COMPANY. The foregoing notwithstanding, without the consent of XXXXXXXXXXXXXXXXXX or TUFTS, COMPANY may make (a) disclosures required by law, (b) factual statements during the TERM that COMPANY has a license from XXXXXXXXX under one or more of the patents and/or patent applications comprising the PATENT RIGHTS, (c) disclosures of the terms of the Agreement to its or its AFFILIATE’S or affiliated entity’s directors, officers, employees, consultants, advisors and agents, or actual or potential licensors, licensees, sublicensees, acquirers, investors and financing sources; provided that, COMPANY shall bind them to reasonable confidentiality obligations. In addition, COMPANY shall have the right to issue a press release upon execution of this Agreement and the achievement of any milestone, which will be reviewed and approved in advance by XXXXXXXXX or TUFTS, if XXXXXXXXX or TUFTS is named in such press release and such naming is not required by law.
7. Section 16.1 (Notice) of the LICENSE is deleted in its entirety and replaced with the following:
Appears in 3 contracts
Samples: Exclusive Patent License Agreement (Rubius Therapeutics, Inc.), Exclusive Patent License Agreement (Rubius Therapeutics, Inc.), Exclusive Patent License Agreement (Rubius Therapeutics, Inc.)